OCWP
IONS icon

Owl Creek Wealth Partners’s Ionis Pharmaceuticals IONS Stock Holding History

Owl Creek Wealth Partners’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.7K Buy
210
+40
+24% +$3.01K ﹤0.01% 685
2026
Q1 		$12.8K Buy
+170
New +$13.4K ﹤0.01% 709

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Owl Creek Wealth Partners's IONS Position: Q2 2026 in Review

Owl Creek Wealth Partners increased its Ionis Pharmaceuticals (IONS) stake by 24% in Q2 2026, buying an estimated $3.01K and bringing the position to 210 shares worth $16.7K. The position accounts for ﹤0.01% of the portfolio, ranked #685.

Owl Creek Wealth Partners first reported a position in IONS in Q1 2026 and has held it in 2 quarters since. 513 funds tracked by Wall St. Rank hold IONS as of Q2 2026.

  • Owl Creek Wealth Partners held 210 shares of Ionis Pharmaceuticals worth $16.7K as of Q2 2026.
  • Owl Creek Wealth Partners bought 40 Ionis Pharmaceuticals shares in Q2 2026, an estimated $3.01K.
  • Ionis Pharmaceuticals made up ﹤0.01% of Owl Creek Wealth Partners's portfolio in Q2 2026, its #685 holding.
  • Owl Creek Wealth Partners first reported a position in Ionis Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 513 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2026.

Based on Owl Creek Wealth Partners's 13F filing for Q2 2026, filed 20 Jul 2026.